Evommune, Inc. (EVMN)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$12.27+2.25%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Achieve at least $13 million revenue in 2026: FY26 revenue guidance $13.0M vs target $13.0M; Q2 FY26 reported revenue $0.0M.
Evommune aims to reach $13 million revenue in 2026. It is advancing Phase 2b data for atopic dermatitis in H2 2026. The company has stable management and a promising drug pipeline.
Revenue is currently zero and may not reach $13 million in 2026. The company is loss-making with negative earnings. Recent trial results and litigation raise risks.
The market expects about 85% revenue decline and negative earnings. Our fair value matches the Street median at $50. We see risk in meeting revenue targets.
Breaks if: Phase 2b data not advanced or negative by end of H2 2026
Focus on advancing the Atopic Dermatitis Phase 2b data expected in H2 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
EVMN represents a speculative growth investment. The company is in the early stages of clinical trials for its products, which could lead to future revenue, but it currently operates at a loss and faces elevated risks.
The market appears to have priced in a low valuation compared to peers, reflecting a justified stance given its recent earnings miss and ongoing financial challenges. There is a low expectations gap, indicating that investors are cautious but not overly pessimistic.
Fundamentals are likely to remain weak in the near term, as the company has reported no revenue and missed earnings expectations recently. However, management is focused on advancing clinical trials, which could provide a path to future growth.
The thesis hinges on the outcomes of ongoing clinical trials and the overall performance of the healthcare sector. Key factors include the potential for EVMN to meet or exceed guidance and the impact of broader economic conditions on investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about future performance. There are no new supportive factors to offset this weakness.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Litigation causes trial delays or material financial loss
Breaks if: revenue falls below $10 million in FY26
In the next 1 to 3 years, EVMN's trajectory will depend heavily on clinical developments and market conditions. Not investment advice.